10 completed, 1 enrolling by invitation. 8 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow selatogrel: new trials by email Literature Review of selatogrel trials Research Report on selatogrel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome Selatogrel, Matching placebo - Chronic Coronary Syndrome | Phase 1 | Completed | Viatris Innovation GmbH | 20 | 2026-06-22 | 2026-10-27 |
| A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants Selatogrel, Matching placebo - Healthy Volunteers | Phase 1 | Completed | Viatris Innovation GmbH | 32 | 2025-10-07 | 2026-07-14 |
| Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Selatogrel, Placebo - Acute Myocardial Infarction | Phase 3 | Enrolling by invitation | Viatris Innovation GmbH | 25000 | 2021-08-14 | 2026-10-27 |
| A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects Selatogrel - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 24 | 2020-11-06 | 2025-07-03 |
| The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics Selatogrel - Healthy Subjects, Hepatic Impairment | Phase 1 | Completed | Viatris Innovation GmbH | 24 | 2020-07-22 | 2025-07-04 |
| A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects Saline, ACT-246475, Rifampicin - Healthy Subject | Phase 1 | Completed | Viatris Innovation GmbH | 14 | 2019-01-03 | 2025-07-03 |
| A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects ACT-246475 - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 6 | 2018-07-27 | 2025-07-03 |
| A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack Selatogrel 8 mg, Selatogrel 16 mg - Acute Myocardial Infarction | Phase 2 | Completed | Viatris Innovation GmbH | 48 | 2018-07-10 | 2026-07-29 |
| A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects ACT-246475, Clopidogrel, Prasugrel - Healthy | Phase 1 | Completed | Viatris Innovation GmbH | 77 | 2018-01-24 | 2025-07-03 |
| A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease Selatogrel, Placebo - Stable Coronary Artery Disease | Phase 2 | Completed | Viatris Innovation GmbH | 346 | 2018-01-24 | 2026-07-29 |
| Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects 5 mg ACT-281959 prodrug formulation I (Group A), 20 mg ACT-281959 prodrug formulation I (Group B), ACT-281959 prodrug formulation I (Groups C to G doses to be defined) - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 49 | 2011-10-01 | 2018-07-10 |
Viatris Innovation GmbH (10) · Idorsia Pharmaceuticals Ltd. (1)
United States (5) · Germany (4) · Netherlands (3) · Belgium (2) · Canada (2) · China (2) · Denmark (2) · France (2) · Israel (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Austria (1) · Brazil (1)
Daniela Baldoni, PharmD PhD (1)
PMID 31994703, PMID 32166864, PMID 32439008, PMID 33412611, PMID 34961905
2017 (2), 2018 (2), 2023 (1)